Company profile
Molecular Partners AG
Molecular Partners is a privately owned biopharmaceutical company, located in Zurich, Switzerland, that is pioneering the development of a novel class of targeted protein therapeutics termed DARPins. DARPins are as target specific and potent as monoclonal antibodies. Yet, being small proteins, they overcome the known limitations of conventional protein-based therapeutic approaches.
Source: startup.ch
Highlights
Innosuisse Certificate
More news about Molecular Partners AG
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
